Dublin-listed healthcare services group Uniphar said 2022 saw strong performance for the group, with organic growth lifting profit despite the “uncertain, challenging period”.
In a trading update for the year, the group, which provides integrated services to more than 200 multinational pharmaceutical and medical technology manufacturers, said the business performed in line with the group’s expectations for 2022. Organic gross profit growth was more than 5 per cent, driven by organic growth across each division, along with the supply chain and retail division‘s outperformance.
The latter will likely be boosted in 2023 by the acquisition of McCauley’s Pharmacy Group, which was cleared earlier this month by competition authorities following the original announcement in September. The deal is expected to close imminently.